A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age
In vaccine-naïve Japanese adults ≥65 years of age, V116 is well tolerated, with a safety profile comparable to PPSV23, and elicits immune responses to all V116 serotypes and the cross-reactive serotype 15B. V116 has the potential to broaden protection against PD in Japan through the inclusion of serotypes responsible for the majority of residual PD in adults.
Authors
- Heather Platt (ORCID: https://orcid.org/0000-0002-0910-6077)
- Michio Yagi
- Rie Igarashi
- Osamu Matsuoka
- Miyuki Sawata
- Satoshi Inoue (ORCID: https://orcid.org/0000-0002-3358-7122)
- Nobuyuki Oshima (ORCID: https://orcid.org/0000-0001-8599-7505)
- Hiroyuki Kishino
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- MSD K.K. (Japan) (JP)
- Kishokai Medical Corporation (JP)
Publication Details
- Journal
- Vaccine
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127456
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Merck Sharp and Dohme